Health Care 2025: PULCZINSKI, DALE

Pulczinski is corporate vice president of Novo Nordisk’s manufacturing facility in Petersburg. The Danish pharmaceutical company bought the former AMPAC Fine Chemicals facility from Seoul-based manufacturing conglomerate SK Group at the end of 2024.

The maker of Wegovy and Ozempic has more than 10,000 employees in the U.S. across 11 manufacturing, research and development and business locations and produces half the world’s insulin. Novo Nordisk reported 2024 net sales of 290.4 billion in Danish krone, equivalent to approximately

$45.3 billion. Of that, its U.S. sales accounted for 167.4 billion in Danish krone, or about $26 billion.

As of May, Novo Nordisk had about 100 employees at the 600,000-square-foot Petersburg facility and was hiring for new positions. The location will focus on increasing development and production of future Novo Nordisk products.

A former U.S. Navy officer and assistant professor of naval science in George Washington University’s Naval ROTC program, Pulczinski has been with Novo Norwdisk for more than 22 years. He most recently oversaw its Durham, North Carolina, facility, which produces oral finished products.

Return to the full list of this category’s recipients.